Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of AML in the status of primary induction failure (i.e. persistent leukemia after 2 courses of induction chemotherapy or persisting bone marrow hypoplasia fol-lowing induction chemotherapy +/-minimal residual disease)~* Age: 18-55 years~* Availability of an HLA identical family donor OR unrelated donor with matching in 10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of 1 allele or antigen mismatch OR family donor with maximum 1 allele mismatch.~* Have adequate renal and hepatic functions as indicated by the following laboratory values:~* Serum creatinine ≤1.0 mg/dL; if serum creatinine \>1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \>60 mL/min/1.73 m² as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female)~* Serum bilirubin ≤1.5 mg/dL × upper limit of normal (ULN)~* Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 × ULN~* Alkaline phosphatase ≤2.5 × ULN~Exclusion Criteria:~* Documented chloroma~* Patients having AML M3~* Documented leukemic infiltration of CNS/cerebrospinal fluid~* Karnofsky performance score below \< 60%~* Acute or chronic heart failure~* HIV infection, chronic viral hepatitis~* Severe neurological or psychiatric disorders~* Any circumstances that preclude the use of the drugs used within the protocol~* Prior allogeneic or autologous stem cell transplantation~* \> 3 courses of prior chemotherapy~* Denied informed consent~* Pregnancy or denied of effective contraceptive method

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).